PHARMACEUTICALS related term(s) Drugs

Addresses

State of the Union: President Biden, S257–S262 [7FE], H729–H735 [7FE]

Amendments

CDC: terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), H750, H753, H754, H755, H756 [8FE]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), consideration (H. Res. 97), H727 [7FE]

DEA: make permanent scheduling of fentanyl-related substances (H.R. 467), H2603, H2604 [25MY]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), consideration (H. Res. 429), H2521 [23MY]

Diseases and disorders: eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), consideration (H. Res. 75), H529 [31JA]

Articles and editorials

COVID–19 Vaccines, Prior Infection Reduce Transmission of Omicron, H546 [31JA]

Fact Check—COVID–19 Vaccines Primarily Designed To Prevent Serious Illness, Death, H1164 [8MR]

Fentanyl Surge Started and Peaked Under Trump Despite GOP Blaming Biden, H2519 [23MY]

Opioid Crisis—Critics Say Trump Fumbled Response to Another Deadly Epidemic, H2519 [23MY]

10 Myths Told by COVID Experts-And Now Debunked, H1167 [8MR]

Updated Covid Boosters Cut the Infection Risk From XBB.1.5 Subvariant by Nearly Half, CDC Finds, H545 [31JA]

Bills and resolutions

Abortion: ensure that women seeking chemical abortions are informed that it may be possible to reverse intended effects of abortion if they change their mind (see H.R. 983), H832 [10FE]

——— preempt State restrictions on dispensing medication abortion (see H.R. 2573), H1717 [10AP]

——— prohibit award of Federal funds to higher education institutions that host or are affiliated with student-based service site that provides abortion drugs or abortions to students or employees (see S. 16), S54 [23JA] (see H.R. 435), H250 [20JA]

——— prohibit chemical abortions (see H.R. 5806), H4854 [28SE]

——— prohibit chemical abortions performed without presence of health care provider (see H.R. 421), H249 [20JA]

——— prohibit declaration of national emergency relative to abortion (see S. 196), S173 [31JA] (see H.R. 1143), H865 [21FE]

Armed Forces: authorize use against those responsible for trafficking fentanyl or fentanyl-related substance into U.S. or carrying out related activities that cause regional destabilization in Western Hemisphere (see H.J. Res. 18), H234 [12JA]

——— establish certain protections for servicemembers, or cadets or midshipmen at military service academies, who refuse to receive coronavirus vaccination (see H.R. 434), H250 [20JA] (see H.R. 881), H780 [8FE]

——— establish certain remedies for certain individuals involuntarily separated from Armed Forces solely on basis of refusing to receive coronavirus vaccinations (see H.R. 3458), H2452 [18MY]

——— furnish stellate ganglion block to veterans and members with post-traumatic stress disorder (see H.R. 3023), H2117 [28AP]

——— provide remedies to members discharged or subject to adverse action under coronavirus vaccine mandate (see S. 29), S74 [24JA] (see H.R. 453), H276 [24JA]

——— reinstate servicemembers involuntarily separated solely due to refusal to receive coronavirus vaccination (see H.R. 297), H203 [11JA] (see H.R. 828), H708 [6FE]

Biomedical Advanced Research and Development Authority: establish program to develop medical countermeasures for viral threats with pandemic potential (see S. 2093), S2185 [21JN] (see H.R. 3832), H2741 [5JN]

Business and industry: improve actions available to eligible product developers in event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development (see S. 1120), S1090 [30MR]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into market (see S. 142), S147 [30JA] (see H.R. 6275), H5544 [7NO]

——— prohibit use of patents, trade secrets, or other intellectual property to inhibit competition (see S. 574), S567 [1MR] (see H.R. 4692), H3640 [17JY]

CDC: accelerate collection and publication of data on suicide and drug overdoses (see H.R. 4710), H3699 [18JY]

——— advance population research for chronic pain (see S. 2922), S4678 [26SE]

——— reauthorize certain substance use disorder prevention programs for pregnant and postpartum women (see S. 3370), S5692 [30NO]

——— reauthorize surveillance and data collection for child, youth, and adult trauma (see H.R. 4057), H2883 [13JN]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (see S. 455), S426 [15FE] (see S. 641), S636 [2MR] (see H.R. 185), H104 [9JA]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), consideration (see H. Res. 97), H737 [7FE]

Center for Biomedical Innovation and Development: establish (see S. 1441), S1533 [4MY]

Children and youth: encourage innovation in development of pediatric drugs and ensure drugs for rare diseases are studied in children and drug companies are accountable for completing pediatric study requirements (see H.R. 6664), H6739 [7DE]

——— prohibit certain coronavirus vaccination mandates and require parental consent for vaccination of minors (see S. 169), S172 [31JA]

China: call on public, private, and nonprofit sectors to take action to counter ‘‘Made in China 2025’’ Plan (see H. Res. 697), H4381 [18SE]

CIA: submit to Congress intelligence assessment on Sinaloa Cartel and Jalisco Cartel (see H.R. 6767), H6941 [13DE]

Colleges and universities: streamline process for institutions to research marijuana (see H.R. 3829), H2741 [5JN]

Commission on Strengthening the Domestic Pharmaceutical Supply Chain: establish (see H.R. 4449), H3159 [30JN]

Contraceptives: preempt State bans on prescription, provision, or use of drug, biological product, or device for contraception if approved, licensed, cleared, or otherwise authorized for human use by FDA for contraception (see H.R. 3471), H2452 [18MY]

Controlled Substances Act: amend to fix technical error in definitions (see S. 223), S204 [1FE] (see H.R. 455), H276 [24JA]

DEA: authorize pharmacies to deliver certain controlled substances to administering practitioner in lieu of delivering such substances to ultimate user (see H.R. 4490), H3171 [6JY]

——— define currently accepted medical use with severe restrictions for controlled substances (see S. 689), S669 [7MR] (see H.R. 1393), H1148 [7MR]

——— include fentanyl-related substances under schedule I of Controlled Substances Act, designating they have high potential for abuse and no medical use (see H.R. 568), H427 [26JA] (see H.R. 1291), H1048 [1MR] (see H.R. 1758), H1408 [23MR]

——— make permanent scheduling of fentanyl-related substances (see S. 1141), S1090 [30MR] (see H.R. 171), H104 [9JA] (see H.R. 467), H276 [24JA] (see H.R. 1580), H1285 [14MR]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), consideration (see H. Res. 429), H2498 [22MY]

——— provide for life imprisonment for certain offenses involving fentanyl (see H.R. 3215), H2307 [11MY]

——— require registrants to decline to fill certain suspicious orders (see H.R. 501), H322 [25JA]

——— review scheduling of buprenorphine-naloxone combination products under Controlled Substances Act (see H.R. 4053), H2883 [13JN]

Dept. of Agriculture: expand medical expense deduction for elderly and disabled persons under Supplemental Nutrition Assistance Program (see S. 2432), S3459 [20JY] (see H.R. 4815), H3888 [20JY]

——— improve Supplemental Nutrition Assistance Program support for women, infants, and children impacted by substance use disorder (see H.R. 5312), H4211 [29AU]

Dept. of Defense: develop plan to ensure adequate supply of medications for military health system (see H.R. 6903), H7007 [22DE]

——— ensure drop boxes are maintained on military installations for deposit of unused prescription drugs (see H.R. 129), H102 [9JA]

——— establish grant program for using psychedelic substances to treat certain conditions (see H.R. 3684), H2636 [25MY]

——— establish pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce reliance on foreign manufacturers for active pharmaceutical ingredients and key starting materials (see H.R. 6897), H7006 [22DE]

——— require responsiveness testing of Defense Logistics Agency pharmaceutical contracts (see S. 1057), S1053 [29MR] (see H.R. 5151), H4164 [4AU]

——— submit report evaluating beneficiary access to TRICARE network pharmacies (see H.R. 5150), H4164 [4AU]

Dept. of Education: prohibit imposition of coronavirus vaccine mandates by higher education institutions (see H.R. 1374), H1113 [3MR]

——— prohibit institutions of higher education from mandating coronavirus vaccines for students or staff (see H.R. 5634), H4455 [21SE]

Dept. of HHS: allow expedited approval of generic prescription drugs and temporary importation of prescription drugs during noncompetitive drug markets and drug shortages (see S. 845), S825 [16MR]

——— authorize certain contracts and cooperative agreements with clinical laboratories for purposes of delivery of medical products to Strategic National Stockpile (see H.R. 3840), H2761 [6JN]

——— authorize fellowships under Minority Fellowship Program to be awarded for training for professionals in addiction medicine field (see S. 3145), S5213 [26OC]

——— award grants to regional biocontainment laboratories for maintaining surge capacity to respond to outbreaks of infectious diseases or acts of bioterrorism (see S. 2538), S3620 [26JY]

——— clarify rules relative to drug discounts for covered entities (see S. 1133), S1090 [30MR]

——— clarify that grants for State and Tribal response to opioid use disorders may be used to address associated health conditions (see H.R. 4489), H3171 [6JY]

——— conduct demonstration program to test providing preferential treatment under Medicare, Medicaid, and Children’s Health Insurance Program for certain drugs and biologicals manufactured in U.S. (see S. 3311), S5540 [15NO]

——— conduct study on designation of biosimilar biological products as interchangeable (see S. 1522), S1602 [10MY]

——— conduct surveys of non-retail pharmacy drug prices (see S. 3245), S5402 [7NO]

——— continue Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (see S. 2434), S3459 [20JY]

——— create plan for completing review of approved opioid analgesic drugs that considers public health effects of such opioid drugs (see S. 3557), S6057 [19DE]

——— delegate primary responsibility for maintaining Strategic National Stockpile to Assistant Secretary for Preparedness and Response (see H.R. 3837), H2761 [6JN]

——— eliminate coronavirus vaccine and mask requirement in Head Start programs (see H.R. 794), H677 [2FE]

——— ensure expenses relating to acquisition or use of devices to detect fentanyl, xylazine, and other emerging adulterant substances, including test strips are allowable expenses under certain grant programs (see S. 2976), S4759 [28SE] (see H.R. 5801), H4854 [28SE]

——— ensure references to opioid overdose reversal agents in grant programs are not limited to naloxone (see S. 2809), S4525 [14SE] (see H.R. 4007), H2807 [12JN]

——— ensure transparency and oversight of 340B drug discount program (see H.R. 3290), H2342 [15MY]

——— establish automated supply-chain tracking application that provides near real-time insight into amount of critical medical and health supplies available in Strategic National Stockpile (see H.R. 3577), H2499 [22MY]

——— establish education partnership programs between public schools and public health agencies to prevent misuse and overdose of synthetic opioids by youth (see H.R. 5625), H4454 [21SE]

——— establish fentanyl lethality awareness campaign, establish Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs, and provide grants to mitigate effects of drug misuse (see S. 1235), S1293 [20AP] (see H.R. 2867), H1947 [25AP]

——— establish grant program for family community organizations that provide support for individuals struggling with substance use disorder and their families (see S. 1810), S1982 [6JN] (see H.R. 3879), H2763 [6JN]

——— establish Office of Drug Manufacturing to manufacture certain generic drugs in order to reduce prices, increase competition, and address shortages in prescription drug market (see S. 3398), S5750 [5DE] (see H.R. 6607), H6144 [5DE]

——— establish program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals (see S. 954), S933 [23MR]

——— establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids (see S. 1785), S1843 [31MY] (see H.R. 3375), H2376 [16MY]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (see S. 2044), S2145 [20JN] (see H.R. 4215), H2990 [20JN]

——— establish requirements relative to prescription drug benefits (see S. 1131), S1090 [30MR]

——— establish State insulin assistance programs, hold manufacturers accountable for excessive insulin price increases, and promote market competition to drive down prices (see S. 1497), S1566 [9MY] (see H.R. 3134), H2170 [9MY]

——— evaluate process by which interchangeable biological products are approved to be used in pharmaceuticals (see H.R. 1790), H1437 [24MR]

——— expand and clarify exclusion for orphan drugs under drug price negotiation program (see S. 3131), S5183 [25OC] (see H.R. 5539), H4380 [18SE]

——— expand drug price negotiation program (see H.R. 4895), H4028 [26JY]

——— extend requirement for State Medicaid plans to provide coverage for medication-assisted treatment (see S. 3136), S5212 [26OC] (see H.R. 3736), H2638 [25MY]

——— improve access to pre-exposure prophylaxis (PrEP) to reduce transmission of HIV (see S. 2188), S2224 [22JN] (see H.R. 4392), H3150 [27JN]

——— improve Organ Procurement and Transplantation Network (see S. 1668), S1705 [17MY] (see S. 2404), S3458 [20JY] (see H.R. 2544), H1716 [10AP]

——— improve patient access to oral medications (see H.R. 4011), H2807 [12JN]

——— improve supply chain resiliency for critical drug products and ensure reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions (see S. 2510), S3619 [26JY] (see H.R. 6802), H6984 [14DE]

——— increase access to medication for opioid overdose reversal (see S. 1373), S1418 [27AP]

——— issue draft guidance to address non-addictive analgesics for chronic pain (see S. 3462), S5897 [11DE]

——— issue guidance on strategies under Medicaid and Children’s Health Insurance Program to increase mental health and substance use disorder care provider education, training, recruitment, and retention (see S. 3158), S5213 [26OC]

——— make updates to National Vaccine Injury Compensation Program (see H.R. 5142), H4164 [4AU]

——— mitigate drug shortages and provide incentives for manufacturing of active pharmaceutical ingredients, excipients, medical devices, pharmaceuticals, and personal protective equipment (see H.R. 2707), H1885 [19AP]

——— prohibit group health plans and health insurance issuers from entering into contracts that prevent or restrict access to drug pricing information available through consumer decision-support tools (see S. 1374), S1418 [27AP]

——— prohibit use of Federal funds to enforce rule on coronavirus vaccine and mask requirements for Head Start programs (see H.R. 1019), H838 [14FE]

——— prohibit use or declaration of public health emergency with respect to abortion (see H.R. 384), H242 [17JA]

——— promote price transparency in health care sector (see H.R. 5378), H4229 [8SE]

——— provide dedicated funding for health advocates to develop targeted outreach, event planning materials, and other resources for community organizations to utilize during National Recovery Month (see S. 2766), S4388 [12SE] (see H.R. 5418), H4263 [12SE] (see H.R. 5452), H4297 [13SE]

——— provide for appropriate cost-sharing for individuals of certain age for insulin products covered under private health plans and Medicaid (see H.R. 1587), H1285 [14MR]

——— provide for appropriate cost-sharing for insulin products covered under private health plans (see S. 954), S933 [23MR]

——— provide for clarity relative to duration of contracts for procurement of supplies for Strategic National Stockpile (see H.R. 4458), H3166 [3JY]

——— provide for stockpiles to ensure that all Americans have access to generic drugs at risk of shortage (see H.R. 405), H248 [20JA]

——— provide funding for trained school personnel to administer drugs and devices for emergency treatment of known or suspected opioid overdose (see S. 2946), S4720 [27SE] (see H.R. 3065), H2125 [2MY]

——— provide grants to medical and other health professional schools to expand or develop education and training programs for substance use prevention and treatment (see H.R. 4918), H4029 [26JY]

——— provide urgent acquisition and deployment authority for purposes of replenishing U.S. stockpiles (see S. 2055), S2145 [20JN]

——— reauthorize and improve pilot program to support State medical stockpiles and ensure public health departments are consulted by Public Health Emergency Medical Countermeasures Enterprise (see S. 2080), S2185 [21JN]

——— reauthorize certain programs relative to public health security and all-hazards preparedness and response (see S. 2333), S2984 [18JY] (see H.R. 4697), H3698 [18JY]

——— reauthorize certain programs under Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (see S. 1991), S2097 [14JN] (see H.R. 4102), H2930 [14JN]

——— reauthorize comprehensive opioid recovery centers (see H.R. 1502), H1247 [9MR]

——— reauthorize pilot program for public health laboratories to detect fentanyl and other synthetic opioids (see H.R. 4063), H2883 [13JN]

——— reauthorize program of preventing overdoses of controlled substances (see H.R. 4099), H2930 [14JN]

——— remove certain liability protections for certain biological products and other drugs if sponsor thereof fails to disclose to public all non-exempt data within biological product file or drug application (see H.R. 5773), H4713 [27SE]

——— report on interoperability of medical devices (see H.R. 1557), H1279 [10MR]

——— require drug manufacturers to include printed inserts containing drug information when they ship their products to pharmacies (see H.R. 1173), H873 [24FE]

——— require drug manufacturers to submit transparency and justification report prior to increasing certain drug prices (see S. 935), S909 [22MR]

——— require funds to be set aside for opioid reversal agent administration training in schools (see H.R. 5652), H4455 [21SE]

——— specify duration of contracts, grants, cooperative agreements, or other transactions awarded or entered into with Biomedical Advanced Research and Development Authority (see H.R. 4459), H3166 [3JY]

——— support endemic fungal disease research, incentivize valley fever vaccine development, and discover new antifungal therapies and diagnostics to fight infections such as Valley Fever (see S. 3464), S5919 [12DE] (see H.R. 6731), H6859 [12DE]

Dept. of Homeland Security: restrict flow of illicit drugs into U.S. (see S. 1464), S1534 [4MY]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (see H.R. 3094), H2134 [5MY]

Dept. of Justice: allow for civil and criminal actions against certain providers of interactive computer services relative to fentanyl trafficking (see S. 2264), S2360 [12JY]

——— authorize use of grants to provide training for first responders on use of containment devices to prevent exposure to fentanyl and other potentially lethal substances and for purchasing such devices (see S. 261), S230 [2FE] (see H.R. 795), H678 [2FE]

——— expand Comprehensive Opioid Abuse Grant Program (see H.R. 6243), H5465 [6NO]

——— improve data on opioid-related overdoses and award grants to local law enforcement agencies in communities with high rates of overdoses (see S. 983), S954 [27MR] (see H.R. 3150), H2171 [9MY]

——— provide for Comprehensive Opioid, Stimulant, and Substance Abuse Program pilot program for local law enforcement agencies in rural areas to purchase naloxone to prevent and reduce opioid overdose deaths (see H.R. 4431), H3158 [30JN]

——— provide grants for drug disposal sites (see H.R. 5615), H4454 [21SE]

——— provide outreach regarding fentanyl, expand Comprehensive Opioid Abuse Grant Program and addiction treatment and recovery services, and enhance penalties for certain offenses involving counterfeit pills (see H.R. 3570), H2499 [22MY] (see H.R. 4272), H3107 [22JN]

——— require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances (see S. 1080), S1088 [30MR]

Dept. of Labor: conduct study on fiduciary duties of pharmacy benefit managers (see S. 3330), S5540 [15NO]

——— issue guidance and regulations regarding opioid overdose reversal medication and employee training (see S. 2948), S4720 [27SE] (see H.R. 5420), H4263 [12SE]

——— issue occupational safety and health standard that requires employers to keep opioid overdose reversal drugs onsite and develop and implement training plans to respond to drug overdose emergencies (see H.R. 6243), H5465 [6NO]

——— prohibit issuance of emergency temporary standard requiring employers to ensure employees receive coronavirus vaccine or testing (see H.R. 526), H323 [25JA]

Dept. of State: designate Mexican cartels and other transnational criminal organizations as foreign terrorist organizations (see S. 1048), S1053 [29MR]

——— impose sanctions on Chinese pharmaceutical companies and certain cartels that traffic fentanyl (see S. 2059), S2145 [20JN]

Dept. of Veterans Affairs: conduct review of deaths of certain veterans who committed suicide (see H.R. 4400), H3157 [30JN]

——— conduct review on opioid overdose deaths among veterans (see H.R. 6353), H5668 [9NO]

——— expand access to Veterans Community Care Program to include certain veterans seeking mental health or substance-use services (see S. 1745), S1745 [18MY] (see H.R. 3554), H2456 [18MY]

Depts. of HHS and State: formulate strategy to secure support from foreign countries, multilateral organizations, and others to facilitate development and commercialization of qualified pandemic or epidemic products (see H.R. 1305), H1048 [1MR]

Diseases and disorders: eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (see H.R. 497), H322 [25JA]

——— eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), consideration (see H. Res. 75), H574 [31JA]

——— facilitate development of treatments for cancers (see S. 642), S636 [2MR] (see H.R. 1780), H1437 [24MR]

——— prohibit any entity that receives Federal funding from coronavirus relief packages from mandating employees receive coronavirus vaccine (see H.R. 117), H102 [9JA]

——— prohibit vaccination mandates for coronavirus (see S. 167), S172 [31JA] (see H.R. 403), H248 [20JA]

——— protect against seasonal and pandemic influenza (see S. 3219), S5338 [2NO] (see H.R. 5846), H4909 [29SE]

——— recognize critical role that President’s Emergency Plan for AIDS (PEPFAR) has played in global fight against HIV/AIDS (see S. Res. 139), S1091 [30MR]

District of Columbia: prohibit use of Federal and local funds for coronavirus vaccine mandate in District of Columbia schools and repeal related legislation enacted by District of Columbia Council (see S. 165), S172 [31JA]

Drugs: address prescription drug shortages and improve quality of prescription drugs (see S. 2586), S3753 [27JY]

——— allow sponsors of certain new drug applications to rely on investigations conducted in certain foreign countries (see S. 1132), S1090 [30MR]

——— amend laws relative to registration of opioid treatment programs to increase stakeholder input from relevant communities and ensure such programs are treating patients in need (see H.R. 2804), H1914 [24AP]

——— clarify possession, sale, purchase, importation, exportation, or transportation of drug testing equipment that tests for presence of fentanyl or xylazine is not unlawful (see S. 2569), S3753 [27JY]

——— combat fentanyl crisis (see S. 2699), S3757 [27JY]

——— ensure comprehensive wraparound services for families impacted by substance use disorders (see S. 3006), S4916 [3OC] (see H.R. 5866), H4950 [2OC]

——— ensure equitable treatment of covered entities and pharmacies participating in 340B drug discount program (see H.R. 2534), H1709 [6AP]

——— ensure that States do not prohibit individuals from obtaining, possessing, distributing, or using life-saving drug testing technologies (see S. 2484), S3522 [25JY]

——— establish patient protections with respect to highly rebated drugs (see H.R. 3285), H2342 [15MY]

——— establish requirements relative to cost-sharing for certain insulin products (see H.R. 1488), H1247 [9MR]

——— express that fentanyl-related substances are a weapon of mass destruction and should be classified as such (see H. Res. 39), H243 [17JA]

——— extend Federal support for bioindustrial manufacturing processes to include support for manufacturing of certain pharmaceutical ingredients (see H.R. 6895), H7006 [22DE]

——— fund detection and testing activities, such as wastewater surveillance, to detect synthetic opioids (see H.R. 4773), H3886 [20JY]

——— increase reporting and transparency requirements in 340B Drug Pricing Program (see S. 1182), S1210 [18AP] (see H.R. 198), H105 [9JA]

——— issue guidance and regulations regarding opioid overdose reversal medication and employee training (see H.R. 5420), H4263 [12SE]

——— limit cost-sharing for prescription drugs (see H.R. 6347), H5668 [9NO]

——— limit price charged by manufacturers for insulin (see S. 727), S742 [9MR] (see H.R. 1485), H1247 [9MR]

——— mitigate effects of coronavirus pandemic on incentives for development of orphan drugs (see H.R. 1805), H1464 [27MR]

——— prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (see S. 1475), S1566 [9MY] (see H.R. 4105), H2930 [14JN]

——— prohibit certain uses of xylazine (see S. 993), S999 [28MR] (see H.R. 1839), H1527 [28MR]

——— prohibit delivery of opioids by means of dark web (see S. 1728), S1744 [18MY] (see H.R. 3587), H2500 [22MY]

——— prohibit distribution and receipt of rebates for prescription drugs (see S. 1217), S1256 [19AP]

——— prohibit manufacturing or distributing candy-flavored controlled substances for minors (see H.R. 757), H675 [2FE]

——— provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage (see S. 2666), S3756 [27JY]

——— reauthorize certain programs to provide for opioid use disorder prevention, recovery, and treatment (see H.R. 4531), H3204 [11JY]

——— reauthorize program to support individuals in substance use disorder treatment and recovery to live independently and participate in workforce (see H.R. 4088), H2930 [14JN]

——— reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (see S. 1269), S1340 [25AP]

——— reduce price of insulin for patients (see S. 146), S147 [30JA]

——— reduce threshold for mandatory minimum penalties for certain fentanyl-related offenses (see H.R. 335), H233 [12JA]

——— reform prescription drug pricing and reduce out-of-pocket costs by ensuring consumers benefit from negotiated rebates by requiring coinsurance obligations be set as percentage of net price not list price (see H.R. 6856), H6997 [19DE]

——— remove cannabis from schedule I under Controlled Substances Act to allow States to determine their own level of cannabis reform (see H.R. 6028), H5042 [24OC]

——— require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to FDA and Patent and Trademark Office (see S. 2780), S4440 [13SE] (see H.R. 5429), H4296 [13SE]

——— require that retail list price for certain prescription drugs and biological products may not exceed average retail list price for such products among certain nations (see S. 1218), S1256 [19AP]

——— study effects of remote monitoring on individuals who are prescribed opioids (see H.R. 4093), H2930 [14JN]

Employment: void existing non-compete agreements for any employee fired for not complying with employer’s coronavirus vaccine mandate (see H.R. 527), H323 [25JA]

FAA: include medications and medical equipment for emergency treatment of known or suspected opioid overdose in aircraft emergency medical kits (see H.R. 3616), H2546 [23MY]

FDA: allow digital communication of prescribing information for drugs, including biological products (see S. 2916), S4678 [26SE] (see H.R. 1503), H1248 [9MR]

——— allow for hemp-derived cannabidiol and hemp-derived cannabidiol containing substances in dietary supplements and food (see S. 2451), S3459 [20JY] (see H.R. 4849), H3948 [25JY]

——— allow rejection of citizen petition if it is believed primary purpose of petition is to delay approval of pending drug application and refer such petitioners to FTC (see S. 1067), S1053 [29MR]

——— allow women greater access to wider range of self-administered contraceptives (see H.R. 1512), H1248 [9MR]

——— amend laws relative to 180-day exclusivity period (see S. 1114), S1089 [30MR]

——— amend mission statement to require agency to address nation’s prescription opioid addiction epidemic (see S. 604), S568 [1MR]

——— clarify process for denying certain petitions whose primary purpose is to delay approval of application submitted relative to certain drugs (see H.R. 3030), H2118 [28AP]

——— deny approval of new drug application for opioid analgesic drug on basis of such drug not being clinically superior to other commercially available drugs (see S. 607), S568 [1MR] (see H.R. 1375), H1113 [3MR]

——— determine whether to permit use of enriched enrollment randomized withdrawal methodology relative to clinical trials (see S. 2737), S4270 [7SE]

——— encourage sponsors of oral contraceptive drugs to submit applications for approval of such drugs as over-the-counter (see H.R. 4626), H3574 [13JY]

——— enhance drug manufacturing amount information reporting (see H.R. 3810), H2740 [5JN]

——— ensure patients have access to certain urgent-use compounded medications (see H.R. 167), H104 [9JA]

——— establish emerging pathogen preparedness program to improve regulatory oversight of medical countermeasures for future pandemics (see S. 2329), S2461 [13JY]

——— establish postmarket reporting requirements for pharmaceuticals (see S. 3143), S5213 [26OC] (see H.R. 6112), H5174 [26OC]

——— establish procedures relative to approval of opioid drugs (see S. 603), S568 [1MR]

——— establish process to allow holders of abbreviated new generic drug applications to make labeling changes to include new or updated safety-related information (see H.R. 4134), H2932 [14JN]

——— establish requirements for purchasing certain generic drugs from manufacturers who produce drug domestically (see S. 2683), S3756 [27JY]

——— establish special rules allowing generic manufacturers to sue brand-name manufacturers who overstate applications concerning method of use patents (see S. 1128), S1090 [30MR]

——— establish time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products (see S. 1906), S2029 [8JN] (see H.R. 4408), H3157 [30JN]

——— expand certain authorities relative to recall of controlled substances to apply with respect to all drugs (see H.R. 2500), H1707 [6AP]

——— improve priority review process of human drug applications to encourage treatment for agents that present national security threats (see S. 1122), S1090 [30MR] (see H.R. 5708), H4497 [26SE]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (see S. 95), S120 [26JA] (see H.R. 427), H249 [20JA]

——— improve requirements for making determination of interchangeability of biological product and its reference product (see S. 2305), S2460 [13JY]

——— issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy (see H.R. 4242), H3070 [21JN]

——— make hemp, cannabidiol derived from hemp, and any other ingredient derived from hemp lawful for use as dietary ingredients in dietary supplements (see H.R. 1629), H1292 [17MR]

——— modernize methods of authenticating controlled substances in pharmaceutical distribution supply chain (see H.R. 4988), H4138 [27JY]

——— nullify modifications made to risk evaluation and mitigation strategy for abortion pill mifepristone (see H.R. 383), H242 [17JA] (see H.R. 5850), H4909 [29SE]

——— permit manufacturers to provide additional warnings on generic drugs in same manner as brand name drugs (see S. 2886), S4654 [21SE]

——— preserve access to abortion medications (see S. 237), S229 [2FE] (see H.R. 767), H676 [2FE] (see H. Con. Res. 33), H1725 [13AP]

——— protect access to kratom (see S. 3039), S4948 [4OC] (see H.R. 5905), H4990 [6OC]

——— provide for mandatory recall authority over regulated drugs and homeopathic products (see H.R. 3688), H2636 [25MY]

——— provide for notification by manufacturers of critical essential medicines of increased demand of such drugs (see S. 2362), S2985 [18JY] (see H.R. 3008), H2117 [28AP]

——— provide increased transparency in generic drug applications (see S. 775), S771 [14MR] (see H.R. 3839), H2761 [6JN]

——— provide marketing reciprocity to certain drugs, biological products, and medical devices authorized to be lawfully marketed abroad (see S. 1712), S1744 [18MY] (see H.R. 3532), H2455 [18MY]

——— reaffirm authority to approve drugs for abortion care (see H. Res. 309), H1887 [19AP]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (see S. 1844), S2005 [7JN] (see H.R. 1418), H1149 [7MR]

——— repeal authority to require that drugs be dispensed only upon prescription (see H.R. 75), H100 [9JA]

——— repeal guidance to require veterinary oversight for use of medically important antimicrobial animal drugs available as over-the-counter products (see H.R. 4012), H2807 [12JN]

——— require label of drug intended for human use to identify each ingredient that is, or is derived directly or indirectly from, major food allergen or gluten-containing grain (see S. 2079), S2185 [21JN] (see H.R. 4263), H3071 [21JN]

——— require manufacturers of life-saving drugs to submit data and information to assess stability of such drugs and determine their longest supported expiration date (see H.R. 3793), H2740 [5JN]

——— require more accurate reporting of abortion drug prescribing and related adverse events (see H.R. 2570), H1717 [10AP]

——— respect scientific judgement that mifepristone is safe and effective and ensure access to lifesaving, time-sensitive medication abortion care in U.S. is equitable and based on science (see S. Res. 510), S5997 [14DE]

——— revoke approval of one opioid pain medication for each new opioid pain medication approved (see S. 606), S568 [1MR]

——— set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions (see S. 1214), S1256 [19AP]

——— strengthen authority relative to foreign drug facility inspections (see S. 1134), S1090 [30MR]

——— strengthen use of patient-experience data within benefit-risk framework for approval of new drugs (see S. 526), S457 [16FE] (see H.R. 1092), H853 [17FE]

FDA and Office of the U.S. Trade Representative: require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on China for finished pharmaceutical products and active pharmaceutical ingredients (see S. 2454), S3459 [20JY]

Federal agencies and departments: limit consideration of marijuana use when making security clearance or employment suitability determination (see H.R. 5040), H4140 [27JY]

——— prohibit from imposing any mandate requiring individuals to receive vaccine that has not been authorized for marketing for at least 10 years (see H.R. 2631), H1758 [17AP]

Federal aid programs: recognize essential benefit of Medicare and Social Security programs to current enrollees and strengthen such programs for future generations (see H. Res. 73), H510 [30JA]

Firearms: protect rights of persons whose use of marijuana is permitted by State or Tribal law to own firearms (see H.R. 2772), H1908 [20AP]

Freedom of religion: prohibit imposition of certain substantial burdens relative to coronavirus vaccine mandates on religious exercise (see S. 492), S456 [16FE]

FTC: deter filing of sham citizen petitions to cover attempt to interfere with approval of competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (see S. 148), S147 [30JA]

——— prevent unfair and deceptive acts or practices and dissemination of false information relative to pharmacy benefit management services for prescription drugs (see S. 127), S121 [26JA]

——— prohibit anticompetitive use of patents, known as product hopping, by drug product manufacturers (see S. 150), S147 [30JA]

——— study role of intermediaries in pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (see S. 113), S121 [26JA]

GAO: conduct review examining Dept. of HHS efforts to ensure that U.S. is prepared to rapidly produce certain medical countermeasures in public health emergency (see H.R. 3703), H2637 [25MY]

——— conduct study and submit report on price-related compensation and payment structures in prescription drug supply chain (see S. 2198), S2224 [22JN]

——— conduct study on naloxone access (see H.R. 4005), H2807 [12JN]

——— require report on effects of fentanyl crisis (see H.R. 5237), H4191 [18AU]

——— study accessibility of substance use disorder treatment and mental health care providers and services for farmers and ranchers (see S. 3206), S5338 [2NO]

——— study and report on efficacy of Federal drug surveillance systems (see H.R. 6045), H5103 [25OC]

——— study sale of illicit drugs online (see S. 2982), S4759 [28SE]

Health: exempt sunscreen from over-the-counter medication bans in schools, encourage community and youth-related entities to provide access to sunscreen and sun-protective clothing, and teach sun-safe behaviors (see H. Res. 365), H2136 [5MY]

——— prohibit consideration of race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, political ideology, or speech in determining eligibility for coronavirus treatments and vaccines (see S. 171), S172 [31JA]

——— prohibit Federal funds from being made available to entities that refuse to provide treatment based on coronavirus vaccination status (see S. 420), S397 [14FE] (see H.R. 991), H837 [14FE]

——— protect individual liberty, ensure privacy, and prohibit discrimination relative to coronavirus vaccination status of individuals (see S. 181), S172 [31JA]

——— review and improve domestic biopharmaceutical manufacturing capabilities and public health and medical preparedness and response (see S. 36), S74 [24JA]

Health care facilities: expand take-home prescribing of methadone through pharmacies (see S. 644), S636 [2MR] (see H.R. 1359), H1113 [3MR]

Health care professionals: clarify training requirements for prescribers of controlled substances (see S. 3550), S5996 [14DE]

Health Resources and Services Administration: modify loan repayment program for substance use disorder treatment workforce to relieve workforce shortages (see S. 462), S455 [16FE] (see H.R. 4933), H4029 [26JY]

——— reauthorize loan repayment program for substance use disorder treatment workforce (see S. 3200), S5338 [2NO] (see H.R. 3355), H2375 [16MY] (see H.R. 4079), H2884 [13JN]

Immigration: terminate requirement for proof of coronavirus vaccination for aliens (see H.R. 4726), H3856 [19JY]

Inflation Reduction Act: repeal (see H.R. 812), H678 [2FE]

——— repeal Medicare prescription drug price control provisions (see S. 2157), S2223 [22JN]

Insurance: apply additional payments, discounts, and other financial assistance towards cost-sharing requirements of health insurance plans (see S. 1375), S1419 [27AP] (see H.R. 830), H708 [6FE]

——— ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care (see S. 1451), S1533 [4MY] (see H.R. 3120), H2135 [5MY]

——— clarify Federal Right To Try laws apply to schedule 1 substances for which phase 1 clinical trial has been completed and provide access to eligible patients to such substances (see H.R. 1825), H1526 [28MR]

——— improve services provided by pharmacy benefit managers (see S. 1542), S1603 [10MY] (see H.R. 6283), H5650 [8NO]

——— increase oversight of pharmacy benefits manager services (see S. 2694), S3756 [27JY] (see H.R. 2679), H1845 [18AP] (see H.R. 4846), H3948 [25JY]

——— provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage (see S. 1339), S1417 [27AP] (see H.R. 4507), H3176 [10JY] (see H.R. 4712), H3699 [18JY]

——— require group health plans and group or individual health insurance coverage to provide coverage for over-the-counter contraceptives (see S. 1698), S1743 [18MY] (see H.R. 3589), H2500 [22MY]

——— require group health plans to provide exceptions process for any medication step therapy protocol (see S. 652), S636 [2MR] (see H.R. 2630), H1725 [13AP]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by health care provider (see S. 2039), S2123 [15JN] (see H.R. 6301), H5651 [8NO]

——— require out-of-network coverage for qualified individuals diagnosed with rare pediatric disease participating in approved clinical trials (see H.R. 5647), H4455 [21SE]

——— require regulations concerning disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services (see S. 1543), S1603 [10MY]

——— strengthen transparency requirements relative to pharmacy benefit managers (see H.R. 2816), H1945 [25AP]

Interstate commerce: authorize regulation relative to food containing cannabidiol derived from hemp (see H.R. 1628), H1292 [17MR]

Medicaid: codify value-based purchasing arrangements and reforms relative to price reporting under such arrangements (see H.R. 2666), H1844 [18AP]

——— encourage appropriate prescribing for victims of opioid overdose (see S. 2481), S3522 [25JY] (see H.R. 4950), H4030 [26JY]

——— expand programs to monitor antipsychotic medications to all beneficiaries (see H.R. 4096), H2930 [14JN]

——— expand required reports on Transformed Medicaid Statistical Information System (T-MSIS) substance use disorder data to include mental health condition data (see H.R. 4091), H2930 [14JN]

——— improve transparency and prevent use of abusive spread pricing and related practices (see S. 1038), S1052 [29MR] (see H.R. 1613), H1292 [17MR]

——— require coverage for annual lung cancer screening with no cost sharing for certain individuals and expand coverage of counseling and pharmacotherapy for cessation of tobacco use (see H.R. 4286), H3108 [22JN]

Medicare: amend timing of changes to annual out-of-pocket threshold for prescription drug benefit and timing of drug price negotiation program (see H.R. 5924), H4998 [11OC]

——— apply prescription drug inflation rebates to drugs furnished in commercial market and change base year for rebate calculations (see S. 1139), S1090 [30MR] (see H.R. 4115), H2931 [14JN]

——— assure pharmacy access and choice for beneficiaries (see S. 2405), S3458 (see S. 2436), S3459 [20JY] (see H.R. 5400), H4262 [12SE]

——— clarify application of in-office ancillary services exception to physician self-referral prohibition for drugs (see S. 3458), S5897 [11DE] (see H.R. 5526), H4379 [18SE]

——— clarify congressional intent and preserve patient access to home infusion therapy (see S. 1976), S2096 [14JN] (see H.R. 4104), H2930 [14JN]

——— coordinate programs to prevent and treat obesity (see S. 2407), S3458 [20JY] (see H.R. 4818), H3888 [20JY]

——— delay implementation of inclusion of oral-only End-Stage Renal Disease (ESRD) related drugs in End-Stage Renal Disease prospective payment system (see H.R. 5074), H4151 [28JY]

——— enforce any willing pharmacy requirements and establish safeguards to ensure patient access to pharmacies in part D (see S. 2052), S2145 [20JN]

——— ensure appropriate cost-sharing for chronic care drugs under part D (see S. 2474), S3521 [25JY] (see H.R. 5376), H4229 [8SE]

——— ensure equitable payment for, and beneficiary access to, diagnostic radiopharmaceuticals under hospital outpatient prospective payment system (see S. 1544), S1603 [10MY] (see H.R. 1199), H914 [27FE]

——— ensure fair assessment of pharmacy performance and quality under part D (see H.R. 5393), H4262 [12SE]

——— ensure Medicare-only PACE program enrollees have choice of prescription drug plans under part D (see S. 1703), S1743 [18MY] (see H.R. 3549), H2456 [18MY]

——— establish cap on costs for covered prescription drugs (see S. 1450), S1533 [4MY]

——— establish certain standards for pharmacy benefit managers under prescription drug program (see H.R. 2880), H2047 [26AP]

——— establish demonstration project to increase access to biosimilar biological products (see H.R. 1352), H1112 [3MR]

——— establish pharmacy benefit manager reporting requirements relative to prescription drug plans and Medicare Advantage prescription drug plans (see S. 2254), S2359 [12JY] (see H.R. 5385), H4262 [12SE]

——— establish requirements relating to responsibility of pharmacy benefit managers under part D (see S. 1967), S2096 [14JN]

——— extend eligibility for certain payment increases for biosimilar biological products (see H.R. 6400), H5855 [14NO]

——— facilitate midyear formulary changes for biosimilars (see H.R. 5372), H4229 [8SE]

——— improve access to opioid use disorder treatment services (see S. 3326), S5540 [15NO]

——— improve oversight of formulary development and management under part D (see S. 2406), S3458 [20JY]

——— limit beneficiary cost-sharing to net price of covered part D drugs (see S. 2456), S3459 [20JY]

——— limit cost sharing for drugs (see H.R. 4881), H3949 [25JY]

——— make premium and cost-sharing subsidies available to low-income part D beneficiaries residing in Puerto Rico or other U.S. territories (see H.R. 4028), H2807 [12JN]

——— prohibit Dept. of HHS from entering into contracts with sponsors of prescription drug plans that have contract with certain pharmacy benefits managers (see H.R. 6844), H6992 [15DE]

——— promote access to opioid treatments and require coverage of medication assisted treatment, overdose reversal medications, and recovery support services by health plans without cost-sharing requirements (see S. 818), S798 [15MR] (see H.R. 1620), H1292 [17MR]

——— promote transparency of common ownership interests under parts C and D (see H.R. 3282), H2342 [15MY]

——— provide coverage of external infusion pumps and non-self-administrable home infusion drugs (see H.R. 5397), H4262 [12SE]

——— provide coverage of pharmacist-administered tests, treatments, and vaccinations (see S. 2477), S3522 [25JY]

——— provide for adjustments to part D cost-sharing reductions for low-income individuals (see H.R. 5386), H4262 [12SE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D (see H.R. 5384), H4262 [12SE]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D (see H.R. 2893), H2048 [26AP]

——— provide for coverage of certain pharmacist services in underserved areas (see S. 1491), S1566 [9MY]

——— provide for patient-focused listening sessions to improve prescription drug plan transparency, access, and choice (see S. 2408), S3458 [20JY]

——— provide for rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation (see S. 2764), S4388 [12SE] (see H.R. 5391), H4262 [12SE]

——— provide for transparency of funds appropriated for purposes of implementing price negotiation program to lower prices for certain high-priced single source drugs (see S. 1589), S1624 [11MY]

——— provide phase-in for plasma-derived products under manufacturer discount program (see H.R. 6465), H5902 [21NO]

——— provide review process for adverse national coverage determinations relative to drug coverage of certain new, innovative treatments (see H.R. 2408), H1690 [30MR]

——— require disclosure of certain ownership information relating to health care provider and pharmacy ownership (see H.R. 4883), H3949 [25JY]

——— require Medicare Payment Advisory Commission submit reports to Congress on arrangements with pharmacy benefit managers relative to prescription drug plans and Medicare Advantage prescription drug plans (see S. 2493), S3522 [25JY]

——— require reporting on enforcement and oversight of pharmacy access requirements under part D (see S. 2939), S4720 [27SE]

——— require sponsors of prescription drug plans and Medicare Advantage organizations offering such plans under part D to include certain drugs and biosimilar biological products on formulary (see S. 2129), S2222 [22JN] (see H.R. 5461), H4344 [14SE]

——— strengthen certain drug pricing reforms (see S. 1246), S1293 [20AP] (see S. 1264), S1340 [25AP]

Medicare/Medicaid: establish requirements relating to pharmacy benefit managers (see S. 2973), S4759 [28SE]

——— expand mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions (see S. 3430), S5851 [7DE]

——— provide coverage of prescription digital therapeutics for treatment of mental health and substance use disorders (see S. 723), S715 [8MR] (see H.R. 1458), H1205 [8MR]

——— provide no-cost coverage for preventive distribution of opioid overdose reversal drugs (see H.R. 5506), H4345 [14SE]

——— refine set of information sources for determining coverage of certain drugs and biologicals used in treatment or management of rare disease or condition (see H.R. 6094), H5173 [26OC]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (see S. 1250), S1294 [20AP] (see H.R. 5958), H5013 [13OC]

National Adult Hepatitis B Vaccination Awareness Day: designate (see S. Res. 180), S1419 [27AP] (see H. Res. 338), H2118 [28AP]

National Fentanyl Awareness Day: designate (see S. Res. 215), S1705 [17MY] (see H. Res. 381), H2172 [9MY]

National Fentanyl Awareness Week: designate (see S. Res. 79), S507 [27FE]

National Naloxone Awareness Day: designate (see S. Res. 250), S2071 [13JN] (see H. Res. 476), H2763 [6JN]

National security: map U.S. pharmaceutical supply chain and use data analytics to identify supply chain vulnerabilities and other national security threats (see S. 2364), S2985 [18JY]

——— require interagency risk assessment of pharmaceutical supply chain to identify and mitigate health and national security risks (see S. 1961), S2071 [13JN]

NIH: conduct or support further comprehensive research for creation of universal influenza vaccine (see S. 3215), S5338 [2NO] (see H.R. 6184), H5362 [2NO]

——— make awards to outstanding scientists, including physician-scientists, to support researchers focusing on pediatric research, including basic, clinical, translational, or pediatric pharmacological research (see S. 2345), S2984 [18JY] (see H.R. 4714), H3699 [18JY]

——— take certain steps to increase clinical trial diversity (see S. 1701), S1743 [18MY] (see H.R. 3503), H2454 [18MY]

——— transfer pharmaceutical civil penalties to Gabriella Miller Kids First Pediatric Research Program Fund (see S. 1624), S1678 [16MY]

Patient Protection and Affordable Care Act: ensure taxpayer funds for health insurance coverage are available only to authorized individuals (see H.R. 5875), H4985 [3OC]

Privacy: prohibit use of Federal funds to maintain or collect information that can be used to identify any individual to whom coronavirus vaccine is administered (see H.R. 72), H100 [9JA]

Rare Disease Day: designate (see H. Res. 181), H970 [28FE]

Research: increase transparency of costs (see S. 1476), S1566 [9MY] (see H.R. 3160), H2171 [9MY]

Safety: end dependence on Chinese pharmaceuticals by encouraging growth of robust domestic medicine supply chain for generic drugs and empower FDA to issue warnings for critical contaminations (see H.R. 5575), H4407 [19SE]

Schools: require that opioid overdose rescue kits be located at public elementary and secondary schools (see H.R. 4240), H3070 [21JN]

Senate: prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (see S. Res. 332), S4270 [7SE]

——— prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages (see S. Res. 336), S4389 [12SE]

Social Security: clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes (see H.R. 4402), H3157 [30JN]

——— reform (see H.R. 671), H575 [31JA]

Sports: protect health and welfare of horses and improve integrity and safety of horseracing by authorizing States to enter into interstate compact to develop and enforce scientific medication control and racetrack safety rules (see H.R. 5693), H4497 [26SE]

Substance Abuse and Mental Health Services Administration: authorize use of certain grants for health care providers to purchase lethal-means safety supplies for children at risk of suicide or overdose (see S. 3364), S5692 [30NO] (see H.R. 6663), H6739 [7DE]

——— award grants to States to expand access to clinically appropriate services for opioid abuse, dependence, or addiction (see H.R. 3412), H2424 [17MY]

——— reauthorize residential treatment program for pregnant and postpartum women (see S. 3447), S5851 [7DE]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: reauthorize (see S. 3393), S5712 [4DE]

——— reauthorize certain programs (see S. 2433), S3459 [20JY] (see S. 3106), S5143 [24OC]

——— reauthorize youth prevention and recovery initiative (see S. 3070), S5087 [18OC] (see H.R. 5598), H4437 [20SE]

Tardive Dyskinesia Awareness Week: designate (see S. Res. 197), S1534 [4MY] (see H. Res. 367), H2136 [5MY]

Taxation: establish excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (see S. 2559), S3752 [27JY]

——— establish generic drugs and biosimilars production credit (see H.R. 6109), H5174 [26OC]

——— include amounts paid for over-the-counter naloxone to qualify for medical expenses deduction (see H.R. 6161), H5228 [1NO]

——— provide authority to add additional vaccines to list of taxable vaccines (see H.R. 5143), H4164 [4AU]

——— restore amount of orphan drug tax credit (see H.R. 1350), H1112 [3MR]

Technology: clarify that artificial intelligence and machine learning technologies can qualify as practitioner eligible to prescribe drugs if State authorized and FDA approved, cleared, or authorized (see H.R. 206), H105 [9JA]

Travel and tourism: prohibit Federal Government from mandating coronavirus vaccination for interstate travel (see S. 899), S860 [21MR]

Veterans: ensure servicemembers granted general discharge under honorable conditions on sole basis of failure to obey lawful order to receive coronavirus vaccine is eligible for certain educational assistance (see H.R. 291), H203 [11JA]

Letters

Animal Drug User Fee Act reauthorization performance goals and procedures fiscal year 2024 through 2028: FDA, S5038–S5042 [17OC]

Animal Generic User Fee Act reauthorization performance goals and procedures fiscal year 2024 through 2028: FDA, S5042 [17OC]

Freedom for Health Care Workers Act: several Representatives, H539 [31JA]

Messages

Budget of the U.S. Government for Fiscal Year 2024: President Biden, S996 [28MR], H1516 [28MR]

National Emergency Relative to Global Illicit Drug Trade: President Biden, S5958 [13DE], H6926 [13DE]

Motions

CDC: terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), H760 [8FE]

Diseases and disorders: eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), H548 [31JA]

Notices

Intention to object to proceeding to S. 1080, require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances to Dept. of Justice: Senator Wyden, S3500 [20JY]

Remarks in House

Abortion: ensure that women seeking chemical abortions are informed that it may be possible to reverse intended effects of abortion if they change their mind (H.R. 983), H270 [24JA]

——— Texas Federal district court decision in Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, H1743 [17AP], H1768, H1790 [18AP], H1874 [19AP], H1889, H1896, H1898 [20AP]

——— Texas Federal district court hearing of Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, H1236 [9MR]

American Pharmacists Month: observance, H5154 [26OC]

Armed Forces: provide remedies to members discharged or subject to adverse action under coronavirus vaccine mandate, H3219 [12JY]

Biden, President: evaluation of administration, H777–H780 [8FE]

——— evaluation of administration relative to coronavirus pandemic, H2109 [28AP]

——— evaluation of administration relative to economy, H742 [8FE]

——— evaluation of administration relative to fentanyl and opioid epidemic, H2586 [24MY]

——— evaluation of administration relative to use of Defense Production Act to boost domestic production of essential medical supplies and medicines, H5933 [28NO]

Business and industry: support fair pricing in coronavirus vaccine sales, H293 [25JA]

CBO: certify that termination of CDC requirement for proof of coronavirus vaccination for foreign travelers will not result in decrease to Social Security benefits, H725 [7FE]

CDC: clarify authority to mandate disease vaccination requirements for foreign travelers, H753 [8FE]

——— clarify that termination of requirement for proof of coronavirus vaccination for foreign travelers shall not impact order to require negative pre-departure coronavirus test for travelers from China, H755, H756 [8FE]

——— eliminate prohibition on future rulemaking relative to requirement for proof of coronavirus vaccination for foreign travelers, H754, H755 [8FE]

——— prohibit funding to implement, promote, or enforce recommendation to add coronavirus vaccine to child and adolescent immunization schedule, H5822 [14NO]

——— report to Congress number of visitors denied entry to U.S. under policy requiring proof of coronavirus vaccination for foreign travelers, H754 [8FE]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), H652 [2FE], H747–H762 [8FE], E103 [7FE], E113 [9FE]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), consideration (H. Res. 97), H720–H728 [7FE]

Centers for Medicare & Medicaid Services: prohibit funding to enforce coronavirus vaccine reporting requirements for ambulatory surgical centers, H5852, H5853 [14NO]

Colleges and universities: prohibit funding for enforcement of coronavirus vaccine mandate as condition of employment or enrollment at institutions of higher education, H5819, H5820 [14NO]

Congress: accomplishments of 117th Congress, H4283–H4289 [13SE]

——— accomplishments of 118th Congress, H4471 [26SE]

Consumers: decision to cap patient out-of-pocket costs for insulin, H1535 [29MR]

DEA: include fentanyl-related substances under schedule I of Controlled Substances Act, designating they have high potential for abuse and no medical use (H.R. 568), H588 [1FE]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), H2485 [22MY], H2507, H2532 [23MY], H2553, H2560, H2561, H2579–H2587, H2591, H2592 [24MY], H2602–H2606, H2625 [25MY], H4353 [18SE], H6745 [11DE], E494, E496, E498 [25MY]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), consideration (H. Res. 429), H2512–H2522 [23MY]

Defense Health Agency: decision by Express Script Holding Co., to eliminate option for TRICARE beneficiaries to obtain prescriptions at pharmacy of their choice, H477–H481 [27JA], H519 [31JA]

Democratic Party: national agenda, H1122 [7MR], H6963 [14DE]

Dept. of Defense: include in research on fentanyl as schedule I drug, H2603, H2604 [25MY]

——— plant-based or psychedelic medical clinical trials funding, H4596, H4597 [27SE]

——— prohibit coronavirus vaccine mandate, H4619, H4620 [27SE]

——— prohibit provision of gender transition procedures, including surgery or medication, through Exceptional Family Member Program, H3510, H3511 [13JY]

——— prohibit provisions of gender transition procedures, including surgery or medication, through Exceptional Family Member Program, H4616, H4617 [27SE]

——— prohibit TRICARE coverage of sex reassignment surgeries and hormone treatment for transgender individuals, H3508, H3509 [13JY]

——— study and report on health conditions arising in members of Armed Forces after administration of coronavirus vaccine, H3538, H3539 [13JY]

Dept. of HHS: certify that termination of CDC requirement for proof of coronavirus vaccination for foreign travelers will not result in increase in hospitalizations, H756 [8FE]

——— establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids (H.R. 3375), H2581, H2584 [24MY]

——— expand and clarify exclusion for orphan drugs under drug price negotiation program (H.R. 5539), H5673 [13NO]

——— funding for States to build or maintain their own medical stockpile through reductions in Strategic National Stockpile funding, H5784 [14NO]

——— improve Organ Procurement and Transplantation Network (H.R. 2544), H3929, H3930 [25JY]

——— prohibit funding for any grant related to any transgenic edible vaccine, H5832 [14NO]

——— Project BioShield funding through reductions in buildings and facilities funding, H5782, H5783 [14NO]

——— promote price transparency in health care sector (H.R. 5378), H4417 [20SE], H6762–H6789 [11DE], H6842 [12DE], E1207 [12DE]

——— reauthorize program of preventing overdoses of controlled substances, H6821 [12DE]

——— Strategic National Stockpile funding through reductions in buildings and facilities funding, H5783, H5784 [14NO]

Dept. of Justice: expedite rule-making process of permanent scheduling of fentanyl-related substances, H2603 [25MY]

——— provide outreach regarding fentanyl, expand Comprehensive Opioid Abuse Grant Program and addiction treatment and recovery services, and enhance penalties for certain offenses involving counterfeit pills (H.R. 3570), H2486 [22MY], H2520 [23MY]

——— provide outreach regarding fentanyl, expand Comprehensive Opioid Abuse Grant Program and addiction treatment and recovery services, and enhance penalties for certain offenses involving counterfeit pills (H.R. 4272), H3130 [23JN]

Dept. of Labor: reduce salary of Assistant Sec. of Labor for Occupational Safety and Health, H5835 [14NO]

Dept. of State: prohibit funding to enforce or implement coronavirus vaccine mandate for international travelers, H4784, H4785 [28SE]

Dept. of Veterans Affairs: conduct studies into efficacy of drugs that have FDA-designated Breakthrough Therapy status to treat post-traumatic stress disorder, H3996 [26JY]

——— prohibit funding to enforce Veterans Health Administration directive relative to coronavirus vaccine mandates, H4003, H4004 [26JY]

Depts. of HHS and Justice: certify that making permanent scheduling of fentanyl-related substances will lead to reduction in overdose deaths, H2604, H2605 [25MY]

Depts. of Labor, HHS, and Education, and related agencies: prohibit funding to enforce coronavirus vaccine mandate, H5823 [14NO]

——— prohibit funding to establish, implement, or enforce any vaccine mandate, H5848 [14NO]

Diseases and disorders: comparison between responses of California and Florida to coronavirus pandemic, H618 [1FE]

——— eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), H539–H551 [31JA], H583 [1FE], E81 [1FE]

——— eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), consideration (H. Res. 75), H520–H529 [31JA]

——— President’s Emergency Plan for AIDS (PEPFAR) funding, H4721 [28SE]

——— prohibit funding to implement coronavirus vaccine mandates, H5618, H5619 [8NO]

——— study safety of coronavirus vaccines, H900 [27FE]

District of Columbia: prohibit funding to require coronavirus vaccinations for students in elementary or secondary schools, H5638, H5639 [8NO]

Drugs: address health risks associated with Delta–8 THC derived from cannabis, H5470 [7NO]

——— address prescription drug shortages, H1471 [28MR], H4468 [26SE]

——— combat fentanyl crisis, H4395 [19SE]

——— combat opioid crisis, H5233 [2NO]

——— establish requirements relative to cost-sharing for certain insulin products, E1105 [15NO]

——— establish requirements relative to cost-sharing for certain insulin products for children, H2983 [20JN]

——— limit price charged by manufacturers for insulin, H5715 [13NO]

——— provide for opioid use disorder prevention, recovery, and treatment, H2580 [24MY]

——— reauthorize certain programs to provide for opioid use disorder prevention, recovery, and treatment (H.R. 4531), H6789–H6798 [11DE], H6821 [12DE]

——— reduce threshold for mandatory minimum penalties for certain fentanyl-related offenses (H.R. 335), H2320 [15MY]

FAA: require airlines to reinstate pilots who were fired or forced to resign because of vaccine mandates, H3820 [19JY]

FDA: allow for hemp-derived cannabidiol and hemp-derived cannabidiol containing substances in dietary supplements and food (S. 2451), E705 [24JY]

——— allow women greater access to wider range of self-administered contraceptives (H.R. 1512), H1263 [10MR]

——— approval of Leqembi to treat Alzheimer’s disease patients, H3183 [11JY]

——— encourage sponsors of oral contraceptive drugs to submit applications for approval of such drugs as over-the-counter (H.R. 4626), H3617 [17JY]

——— modernize methods of authenticating controlled substances in pharmaceutical distribution supply chain (H.R. 4988), H5973 [29NO]

——— nullify modifications made to risk evaluation and mitigation strategy for abortion pill mifepristone, H4510 [26SE]

——— preserve access to abortion medications, H472 [27JA], H1743 [17AP], H1874, H1875 [19AP], H1889, H1896, H1898 [20AP]

——— prohibit funding for grants relative to any transgenic edible vaccine, H4559, H4560 [26SE]

——— prohibit Unapproved Drugs Initiative implementation funding, H4542 [26SE]

——— prohibit use and distribution of abortion drugs, H3901 [25JY]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (H.R. 1418), H3620–H3624 [17JY]

——— reduce salary of Center for Drug Evaluation and Research Director, H4559 [26SE]

——— reduce salary of Division of Risk Management Director, H4562 [26SE]

——— reduce salary of Office of Compliance Director, H4562 [26SE]

——— reduce salary of Office of Medical Policy Director, H4563 [26SE]

——— reduce salary of Office of New Drugs Director, H4562 [26SE]

——— reduce salary of Office of Regulatory Policy Director, H4563 [26SE]

——— reduce salary of Office of Surveillance and Epidemiology Director, H4561 [26SE]

Federal agencies and departments: include any rule likely to increase mandatory vaccinations in requirement for congressional joint resolution of approval for major rules, H2914, H2915 [14JN]

——— prohibit from imposing any mandate requiring individuals to receive vaccine that has not been authorized for marketing for at least 10 years (H.R. 2631), H2044 [26AP]

Fentanyl Prevention Caucus: launch, H1254 [10MR]

Health: reduce prescription drug and health care costs, H805 [9FE]

House of Representatives: legislative priorities, H5954 [29NO]

Inflation Reduction Act: impact, H653 [2FE]

Insurance: apply additional payments, discounts, and other financial assistance towards cost-sharing requirements of health insurance plans (H.R. 830), H2466 [22MY], E249 [23MR]

——— clarify Federal Right To Try laws apply to schedule 1 substances for which phase 1 clinical trial has been completed and provide access to eligible patients to such substances (H.R. 1825), E267 [28MR]

Medicaid: prohibit funding to finalize, implement, or enforce proposed rule relative to drug rebate program, H5837 [14NO]

——— require coverage for annual lung cancer screening with no cost sharing for certain individuals and expand coverage of counseling and pharmacotherapy for cessation of tobacco use (H.R. 4286), H3001 [21JN]

Medicare: coordinate programs to prevent and treat obesity (H.R. 4818), H3956 [26JY]

Pinckneyville, IL: anniversary of Stotlar Pharmacy (business), E655 [11JY]

Rare Disease Day: designate (H. Res. 181), E161 [28FE]

Republican Party: national agenda, H585 [1FE]

Rocky Mount, NC: express condolences to victims of and commend response to tornado affecting Pfizer, Inc., facility, and recognize company’s continued investment in local economy, H4016 [26JY]

Social Security: reform, H589 [1FE], H653, H654 [2FE]

Technology: invest in current technologies that streamline Federal programs, increase carbon reduction, and aid in development of vaccines, H6852–H6854 [12DE]

Remarks in Senate

Abortion: Texas Federal district court decision in Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, S1123 [17AP]

——— Texas Federal district court hearing of Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, S416 [15FE], S438–S441 [16FE], S836 [16MR]

Armed Forces: provide remedies to members discharged or subject to adverse action under coronavirus vaccine mandate (S. 29), S248 [7FE]

Biden, President: evaluation of administration relative to abortion, S2172–S2174 [21JN]

——— evaluation of administration relative to economy, S4258 [7SE]

——— evaluation of administration relative to prescription drug costs, S5904 [12DE]

——— State of the Union Message, S245 [7FE]

Business and industry: prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into market (S. 142), S218 [2FE]

CDC: terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), S332 [9FE], S361 [13FE], S896–S898 [22MR], S1073–S1075 [30MR]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), unanimous-consent request, S897 [22MR], S1074 [30MR]

Children and youth: prohibit certain coronavirus vaccination mandates and require parental consent for vaccination of minors (S. 169), S248 [7FE]

Congress: accomplishments of 118th Congress, S1620 [11MY]

Consumers: decision to cap patient out-of-pocket costs for insulin, S616 [2MR], S645 [6MR], S756 [14MR], S810 [16MR]

Controlled Substances Act: amend to fix technical error in definitions (S. 223), S192 [1FE]

Democratic Party: national agenda, S406 [15FE]

Dept. of Defense: effect of coronavirus vaccine mandate, S4341 [11SE]

——— enable servicemembers discharged or subject to adverse action under coronavirus vaccine mandate to seek reinstatement, change in discharge status, and restoration of lost benefits, S3586 [26JY]

Dept. of HHS: establish program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals (S. 954), S5498–S5500 [14NO]

——— improve Organ Procurement and Transplantation Network (H.R. 2544), S3731–S3733 [27JY]

——— improve Organ Procurement and Transplantation Network (H.R. 2544), unanimous-consent request, S3731, S3732 [27JY]

——— improve Organ Procurement and Transplantation Network (S. 1668), S5940, S5941 [13DE]

——— provide for appropriate cost-sharing for insulin products covered under Medicare part D and private health plans, S219 [2FE], S616 [2MR], S756 [14MR], S810 [16MR]

——— provide for appropriate cost-sharing for insulin products covered under private health plans (S. 954), S5498–S5500 [14NO]

Dept. of Justice: authorize use of grants to provide training for first responders on use of containment devices to prevent exposure to fentanyl and other potentially lethal substances and for purchasing such devices (S. 261), S1641 [15MY]

——— require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances (S. 1080), S1563 [9MY], S3454 [20JY]

Dept. of State: designate Mexican cartels and other transnational criminal organizations as foreign terrorist organizations (S. 1048), S1559 [9MY]

Diseases and disorders: end coronavirus vaccine mandates, S247–S249 [7FE]

——— President’s Emergency Plan for AIDS (PEPFAR) funding, S5221 [30OC]

——— prohibit vaccination mandates for coronavirus (S. 167), S248 [7FE]

District of Columbia: prohibit use of Federal and local funds for coronavirus vaccine mandate in District of Columbia schools and repeal related legislation enacted by District of Columbia Council (S. 165), S248 [7FE]

Drugs: address drug abuse epidemic by securing southern border, S1229 [19AP]

——— address prescription drug shortages, S2023–S2025 [8JN]

——— lower prescription drug costs for consumers, S412–S414 [15FE], S616 [2MR], S4644 [21SE]

——— prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (S. 1475), S1563 [9MY]

——— reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (S. 1269), S1332–S1334 [25AP]

Economy: national objectives priority assignments, S3577–S3579 [26JY]

FDA: establish time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products, S412 [15FE]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine, S68, S69 [24JA]

——— preserve access to abortion medications, S630 [2MR]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (S. 1844), S5038 [17OC]

FEMA: prohibit award of firefighter assistance grants to fire departments that dismissed employees for not complying with coronavirus vaccine mandate, S1225, S1226 [19AP]

Health: prohibit consideration of race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, political ideology, or speech in determining eligibility for coronavirus treatments and vaccines (S. 171), S248 [7FE]

——— protect individual liberty, ensure privacy, and prohibit discrimination relative to coronavirus vaccination status of individuals (S. 181), S248 [7FE]

Inflation Reduction Act: impact, S189 [1FE], S4213 [6SE], S5722–S5725 [5DE], S5903 [12DE]

Insurance: limit role of pharmacy benefit managers and support market-based pricing, S3440–S3442 [20JY]

——— provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage, S4735 [28SE]

Kansas: tribute to One Pill Can Kill fentanyl awareness campaign, S4222 [6SE]

Medicare: anniversary of Part D prescription drug benefit, S5841, S5842 [7DE]

——— implementation of drug price negotiation program, S3877 [5SE], S4245–S4247 [7SE], S4374–S4380 [12SE], S4610, S4611 [20SE]

——— improve access to opioid use disorder treatment services (S. 3326), S5549 [15NO]

Medicare/Medicaid: lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers, S645 [6MR]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (S. 1250), S1297 [20AP], S4246 [7SE], S5624–S5627 [28NO]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (S. 1250), unanimous-consent request, S5625 [28NO]

National Fentanyl Awareness Day: designate (S. Res. 215), S1712 [17MY]

——— observance, S1563 [9MY]

National Naloxone Awareness Day: designate (S. Res. 250), S2076 [13JN]

National objectives: improve health care services, S4342 [11SE], S5382 [7NO]

Priest River, ID: tribute to White Cross Pharmacy, S5638 [28NO]

Senate: legislative priorities, S1736 [18MY], S3869 [5SE]

——— prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (S. Res. 332), S4248–S4252 [7SE]

——— prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (S. Res. 332), unanimous-consent request, S4251 [7SE]

——— prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages (S. Res. 336), S4369–S4372 [12SE], S4572–S4575 [19SE], S5943–S5946 [13DE]

——— prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages (S. Res. 336), unanimous-consent request, S4371 [12SE], S4574 [19SE], S5944, S5945 [13DE]

Reports

Office of National Drug Control Policy Should Develop Key Planning Elements To Meet Statutory Requirements: GAO, H2514–H2516 [23MY]

Reports filed

Affordable Prescriptions for Patients Act: Committee on the Judiciary (Senate) (S. 150), S567 [1MR]

Better Mental Health Care, Lower-Cost Drugs, and Extenders Act: Committee on Finance (Senate) (S. 3430) (S. Rept. 118–121), S5850 [7DE]

Block, Report, and Suspend Suspicious Shipments Act: Committee on Energy and Commerce (House) (H.R. 501) (H. Rept. 118–66), H2422 [17MY]

Consideration of H.R. 185, Terminate CDC Requirement for Proof of Coronavirus Vaccination for Foreign Travelers: Committee on Rules (House) (H. Res. 97) (H. Rept. 118–3), H737 [7FE]

Consideration of H.R. 467, Halt All Lethal Trafficking of (HALT) Fentanyl Act: Committee on Rules (House) (H. Res. 429) (H. Rept. 118–76), H2498 [22MY]

Consideration of H.R. 497, Freedom for Health Care Workers Act: Committee on Rules (House) (H. Res. 75) (H. Rept. 118–1), H574 [31JA]

Enhancing DHS Drug Seizures Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 1464) (S. Rept. 118–104), S4916 [3OC]

Ensuring Timely Access to Generics Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1067), S2221 [22JN]

Expanding Access to Low-Cost Generics Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1114), S2221 [22JN]

FDA User Fee Programs Relating to New Animal Drugs and Generic New Animal Drugs Reauthorization: Committee on Energy and Commerce (House) (H.R. 1418) (H. Rept. 118–104), H2785 [9JN]

——— Committee on Health, Education, Labor, and Pensions (Senate) (S. 1844), S3618 [26JY]

Halt All Lethal Trafficking of (HALT) Fentanyl Act: Committee on Energy and Commerce (House) (H.R. 467) (H. Rept. 118–67), H2423 [17MY]

Kids First Research Act 2.0: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1624), S4947 [4OC]

Modernizing and Ensuring PBM Accountability Act: Committee on Finance (Senate) (S. 2973) (S. Rept. 118–122), S5850 [7DE]

Pandemic and All-Hazards Preparedness and Response Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2333), S4227 [6SE]

Pharmacy Benefit Manager Reform Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1339), S2221 [22JN]

Pharmacy Benefit Manager Transparency Act: Committee on Commerce, Science, and Transportation (Senate) (S. 127), S5960 [13DE]

Prescription Pricing for the People Act: Committee on the Judiciary (Senate) (S. 113), S567 [1MR]

Preserve Access to Affordable Generics and Biosimilars Act: Committee on the Judiciary (Senate) (S. 142), S567 [1MR]

Require Electronic Communication Service Providers and Remote Computing Services To Report Unlawful Sale and Distribution of Controlled Substances: Committee on the Judiciary (Senate) (S. 1080), S3894 [5SE]

Retaining Access and Restoring Exclusivity (RARE) Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1214), S2221 [22JN]

Securing the U.S. Organ Procurement and Transplantation Network Act: Committee on Energy and Commerce (House) (H.R. 2544) (H. Rept. 118–140), H3204 [11JY]

Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act: Committee on the Judiciary (Senate) (S. 148), S567 [1MR]

Statements

International Health Regulations Emergency Committee Regarding the Coronavirus Disease (COVID–19) Pandemic: WHO, H749 [8FE]

Managing SARS-CoV–2 Exposures: CDC, H749 [8FE]

Terminate CDC Requirement for Proof of Coronavirus Vaccination for Foreign Traveler: Senator Sanders, S1074 [30MR]

Tables

Estimated budget effects of Inflation Reduction Act, H2028 [26AP]

Texts of

H. Res. 75, consideration of H.R. 497, Freedom for Health Care Workers Act, H520 [31JA]

H. Res. 97, consideration of H.R. 185, terminate CDC requirement for proof of coronavirus vaccination for foreign travelers, H720 [7FE]

H. Res. 429, consideration of H.R. 467, Halt All Lethal Trafficking of (HALT) Fentanyl Act, H2512 [23MY]

H.R. 185, terminate CDC requirement for proof of coronavirus vaccination for foreign travelers, H752 [8FE]

H.R. 497, Freedom for Health Care Workers Act, H539 [31JA]

H.R. 1418, FDA user fee programs relating to new animal drugs and generic new animal drugs reauthorization, H3620–H3623 [17JY]

H.R. 2544, Securing the U.S. Organ Procurement and Transplantation Network Act, H3929 [25JY]

H.R. 4531, certain programs to provide for opioid use disorder prevention, recovery, and treatment reauthorization, H6790–H6794 [11DE]

H.R. 5378, Lower Costs, More Transparency Act, H6762–H6785 [11DE]

S. 223, amend Controlled Substances Act to fix technical error in definitions, S192 [1FE]

S. 1250, Drug-Price Transparency for Consumers (DTC) Act, S1297 [20AP]

S. 1991, Comprehensive Addiction Recovery Through Effective Employment and Reentry (CAREER) Act, S2099 [14JN]

S. 2405, Strengthening Pharmacy Access for Seniors Act, S3461 [20JY]

S. 2477, Equitable Community Access to Pharmacist Services Act, S3525 [25JY]

S. Res. 79, National Fentanyl Awareness Week, S507 [27FE]

S. Res. 139, recognize critical role that President’s Emergency Plan for AIDS (PEPFAR) has played in global fight against HIV/AIDS, S1096 [30MR]

S. Res. 180, National Adult Hepatitis B Vaccination Awareness Day, S1422 [27AP]

S. Res. 197, Tardive Dyskinesia Awareness Week, S1537 [4MY]

S. Res. 215, National Fentanyl Awareness Day, S1709 [17MY]

S. Res. 250, National Naloxone Awareness Day, S2075 [13JN]

S. Res. 332, prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages, S4272 [7SE]

S. Res. 336, prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages, S4391 [12SE]

S. Res. 510, respect FDA scientific judgement that mifepristone is safe and effective and ensure access to lifesaving, time-sensitive medication abortion care in U.S. is equitable and based on science, S6004 [14DE]